PMID- 16684481
OWN - NLM
STAT- MEDLINE
DCOM- 20060713
LR  - 20061115
IS  - 1646-0758 (Electronic)
IS  - 0870-399X (Linking)
VI  - 18
IP  - 6
DP  - 2005 Nov-Dec
TI  - [Determination of HER2 by fluorescence in situ hybridization (FISH) in breast 
      cancer. Experience of the Reference Laboratory of Lisbon].
PG  - 417-22
AB  - The knowledgement of HER2/c-erbB-2 status in breast cancer is essential for the 
      eligibility of the patients for therapy with monoclonal antibody 
      anti-HER-2/trastuzumab. From the various existent techniques for the 
      determination of HER-2, the most widely used are: immunohistochemistry (IHC), 
      that estimates the protein expression, and in situ hybridization (FISH), that 
      evaluates its amplification. FISH is essential as complementary of IHQ in tumors 
      with equivocal or non interpreted staining, and also in those with complete weak 
      to moderate membrane staining in >10 % of neoplastic cells (score 2+) because, of 
      these, only cases with gene amplification (FISH positive) respond to therapy. 
      Recent studies also support that FISH should be performed in cases with score 3+, 
      because 10-12% of them don't have amplification. The expensive equipment and 
      reagents for standard FISH method and the need of extensive training and 
      expertise for both the technique and the evaluation, justify a centralized 
      testing in Reference Laboratories. Our aim was to describe the work of the 
      Department of Pathology of the Portuguese Institute of Oncology of Lisbon as a 
      Reference Laboratory in the execution of FISH technique and to present the 
      results obtained from May 2001 to August 2004. FISH was performed with Kit INFORM 
      HER2/neu Gene Detection System, using the BenckMark system of Ventana. We 
      evaluated a series of 4499 invasive carcinoma primary of the breast, that 
      included 587 cases of the Portuguese Institute of Oncology of Lisboa and 3912 
      cases from different Hospitals of Lisboa, Cascais, Almada, Barreiro, Santarem, 
      Evora, Faro, Portimao, Guimaraes, Funchal and Angra do Heroismo. We verified that 
      591 cases (13.5%) had HER2 gene amplification, being those patients eligible for 
      therapy with trastuzumab.
FAU - Andre, Saudade
AU  - Andre S
AD  - Servico de Anatomia Patologica, Instituto Portugues de Oncologia de Francisco 
      Gentil, S.A. Lisboa.
FAU - Tomas, Ana Raquel
AU  - Tomas AR
FAU - Fonseca, Ricardo
AU  - Fonseca R
LA  - por
PT  - English Abstract
PT  - Journal Article
TT  - Carcinoma da mama determinacao da amplificacao do HER2 por hibridacao in situ de 
      fluorescencia (FISH).
DEP - 20060306
PL  - Portugal
TA  - Acta Med Port
JT  - Acta medica portuguesa
JID - 7906803
SB  - IM
MH  - Breast Neoplasms/*genetics/pathology
MH  - Breast Neoplasms, Male/genetics/pathology
MH  - Carcinoma, Ductal, Breast/*genetics/pathology
MH  - Female
MH  - Genes, erbB-2/*genetics
MH  - Humans
MH  - *In Situ Hybridization, Fluorescence
MH  - Male
MH  - Portugal
EDAT- 2006/05/11 09:00
MHDA- 2006/07/14 09:00
CRDT- 2006/05/11 09:00
PHST- 2006/05/11 09:00 [pubmed]
PHST- 2006/07/14 09:00 [medline]
PHST- 2006/05/11 09:00 [entrez]
PST - ppublish
SO  - Acta Med Port. 2005 Nov-Dec;18(6):417-22. Epub 2006 Mar 6.